SAN DIEGO, March 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability ...

With Neurocrine Biosciences having finally shaken up treatment for a rare genetic hormone disease, Harbour BioMed’s antibody offshoot has sold the rights for its own preclinical therapy option ...

SAN DIEGO, Feb. 25, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. (PRNewsfoto ...

JPMorgan lowered the firm’s price target on Neurocrine (NBIX) to $183 from $191 and keeps an Overweight rating on the shares. The firm updated the company’s model to include Ingrezza revenue ...

SAN DIEGO, Feb. 25, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. The live webcasts can be accessed on Neurocrine ...

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine ...

In this article, we are going to take a look at where Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stands against the other fast growth stocks to buy right now. In the fourth quarter of 2024 ...

Analysts' ratings for Neurocrine Biosciences NBIX over the last quarter vary from bullish to bearish, as provided by 15 analysts. The table below offers a condensed view of their recent ratings ...

Neurocrine (NBIX) Biosciences announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares ...

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which ...